Elshazly A, Xu J, Melhem N, Abdulnaby A, Elzahed A, Saleh T
Cancers (Basel). 2024; 16(17).
PMID: 39272847
PMC: 11394573.
DOI: 10.3390/cancers16172989.
Tungjitviboonkun S, Wachirapornpruet P, Unsuwan S
Cureus. 2024; 16(4):e58972.
PMID: 38800235
PMC: 11127122.
DOI: 10.7759/cureus.58972.
Kato K, Takagi S, Takano H, Tsunoda S, Watanabe O, Yamaguchi K
Int J Hematol. 2024; 119(2):205-209.
PMID: 38236369
DOI: 10.1007/s12185-023-03691-y.
Hauser K, Negron C, Albanese S, Ray S, Steinbrecher T, Abel R
Commun Biol. 2018; 1:70.
PMID: 30159405
PMC: 6110136.
DOI: 10.1038/s42003-018-0075-x.
Woywod C, Gruber F, Engh R, Fla T
PLoS One. 2017; 12(7):e0179700.
PMID: 28678800
PMC: 5497988.
DOI: 10.1371/journal.pone.0179700.
[A multicenter comparison study on the detection of BCR-ABL tyrosine kinase domain point mutation].
Qin Y, Wang D, Qiao C, Shen H, Geng S, Cao Z
Zhonghua Xue Ye Xue Za Zhi. 2015; 36(11):902-5.
PMID: 26632460
PMC: 7342421.
DOI: 10.3760/cma.j.issn.0253-2727.2015.11.003.
Patients with Philadelphia-positive leukemia with BCR-ABL kinase mutations before allogeneic transplantation predominantly relapse with the same mutation.
Egan D, Beppu L, Radich J
Biol Blood Marrow Transplant. 2014; 21(1):184-9.
PMID: 25300870
PMC: 4464836.
DOI: 10.1016/j.bbmt.2014.09.012.
Rapid identification of compound mutations in patients with Philadelphia-positive leukaemias by long-range next generation sequencing.
Kastner R, Zopf A, Preuner S, Proll J, Niklas N, Foskett P
Eur J Cancer. 2013; 50(4):793-800.
PMID: 24365090
PMC: 4961242.
DOI: 10.1016/j.ejca.2013.11.030.
Characterization of ABL exon 7 deletion by molecular genetic and bioinformatic methods reveals no association with imatinib resistance in chronic myeloid leukemia.
Meggyesi N, Kalmar L, Fekete S, Masszi T, Tordai A, Andrikovics H
Med Oncol. 2011; 29(3):2136-42.
PMID: 22038725
DOI: 10.1007/s12032-011-0092-9.
Alternative splicing in oncogenic kinases: from physiological functions to cancer.
Druillennec S, Dorard C, Eychene A
J Nucleic Acids. 2011; 2012:639062.
PMID: 22007291
PMC: 3189609.
DOI: 10.1155/2012/639062.
Effector caspases and leukemia.
Lu Y, Chen G
Int J Cell Biol. 2011; 2011:738301.
PMID: 21647292
PMC: 3103908.
DOI: 10.1155/2011/738301.
BCR-ABL isoforms associated with intrinsic or acquired resistance to imatinib: more heterogeneous than just ABL kinase domain point mutations?.
Gruber F, Lundan T, Goll R, Silye A, Mikkola I, Rekvig O
Med Oncol. 2011; 29(1):219-26.
PMID: 21221851
DOI: 10.1007/s12032-010-9781-z.
Detection of twelve nucleotides insertion in the BCR-ABL kinase domain in an imatinib-resistant but dasatinib-sensitive patient with bi-phenotypic acute leukemia.
Hayette S, Chabane K, Tchirkov A, Berger M, Nicolini F, Tournilhac O
Haematologica. 2009; 94(9):1324-6.
PMID: 19734429
PMC: 2738731.
DOI: 10.3324/haematol.2009.007864.
BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitors.
Ma W, Kantarjian H, Yeh C, Zhang Z, Cortes J, Albitar M
Acta Haematol. 2009; 121(1):27-31.
PMID: 19332983
PMC: 2790522.
DOI: 10.1159/000210060.
ExonMiner: Web service for analysis of GeneChip Exon array data.
Numata K, Yoshida R, Nagasaki M, Saito A, Imoto S, Miyano S
BMC Bioinformatics. 2008; 9:494.
PMID: 19036125
PMC: 2621370.
DOI: 10.1186/1471-2105-9-494.
Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia.
Kaur P, Feldhahn N, Zhang B, Trageser D, Muschen M, Pertz V
Mol Cancer. 2007; 6:67.
PMID: 17958915
PMC: 2169263.
DOI: 10.1186/1476-4598-6-67.
